GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2007

Lilly Taps Aveo to Ascertain Response to Its Oncology Drug Candidate

  • Eli Lilly will use Aveo Pharmaceuticals’ technology to more effectively guide the clinical development of one of its cancer compounds.

    Under the collaboration, Lilly will use the Human Response Platform as part of a pilot project. Lilly hopes to identify genetic profiles that correlate with drug response.

    “This latest collaboration with a global pharmaceutical company indicates the opportunity that our platform provides our select partners and AVEO to increase the efficiency and probability of success of drug development in oncology,” points out Tuan Ha-Ngoc, president and CEO of Aveo. “Ultimately, we believe this will enable us to bring the right drugs to the right patients.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using Pet Dogs with Cancer in Preclinical Trials

Do you agree that pet dogs with cancer should be used in early cancer drug trials?

More »